Drug Trial Radar · NCT05712902
Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)
Last checked: Nov 20, 2026Latest source record: Dec 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
104
Actual
Start
Jul 19, 2021
Primary completion
Oct 17, 2022
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Dizal PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Feb 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II, single-arm, multi-center clinical study to evaluate the anti-tumor efficacy, safety, tolerability and pharmacokinetics of Sunvozertinib in participants with locally advanced or metastatic NSCLC carrying EGFR exon 20 insertion mutations whose disease has progressed on prior platinum-based chemotherapy
Conditions
- Non-Small Cell Lung Cancer
Interventions
SunvozertinibDrug
Daily dose of Sunvozertinib
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) according to RECIST 1.1 by an Independent Review Committee (IRC)Time frame: From first dosing until disease progression or intolerable adverse events
Locations
33 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, China
Beijing Chest Hospital,Capital Medical University
Beijing, China
Peking Union Medical College Hospital
Beijing, China
Peking University Third Hospital
Beijing, China
Jilin Cancer Hospital
Changchun, China
Hunan Cancer Hospital(The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
Changsha, China
West China Hospital of Sichuan University
Chengdu, China
Army Medical Center of PLA
Chongqing, China
Chongqing University Cancer Hospital(Chongqing Cancer Hospital)
Chongqing, China
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, China
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, China
Hainan General Hospital
Haikou, China
The First Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, China
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, China
Zhejiang Cancer Hospital (Cancer Hospital of the University of Chinese Academy of Sciences)
Hangzhou, China
Harbin Medical University Cancer Hospital
Harbin, China
The Second Hospital of Anhui Medical University
Hefei, China
The Affiliated Hospital of Inner Mongolia Medical University
Hohhot, China
Jinan Central Hospital (Central Hospital Affiliated to Shandong First Medical University)
Jinan, China
Yunnan Cancer Hospital
Kunming, China
The First Affiliated Hospital of Nanchang University
Nanchang, China
The Second Affiliated Hospital of Nanchang University
Nanchang, China
Fudan University Shanghai Cancer Center
Shanghai, China
The First Hospital of China Medical University
Shenyang, China
The Fourth Hospital of Hebei Medical University
Shijiazhuang, China
The First Affiliated Hospital of Soochow University
Suzhou, China
Shanxi Provincial Cancer Hospital
Taiyuan, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
The Affiliated Cancer Hospital of Xinjiang Medical University
Ürümqi, China
Hubei Cancer Hospital
Wuhan, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
Affiliated Cancer Hospital of Zhengzhou University(Henan Cancer Hospital)
Zhengzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.